Zydus Cadila receives tentative approval from USFDA for Eluxadoline Tablets

Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Eluxadoline Tablets in the strengths of 75 mg and 100 mg (US RLD: VIBERZI® Tablets). Zydus' Eluxadoline Tablets are indicated in adults for the treatment of irritable bowel syndrome with diarrhea, or IBS-D. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 324 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 492.10 as compared to the previous close of Rs. 502.15. The total number of shares traded during the day was 87220 in over 3175 trades.

The stock hit an intraday high of Rs. 501.55 and intraday low of 491.40. The net turnover during the day was Rs. 43276379.00.

Source : Equity Bulls

Keywords

CadilaHealthcareLimited INE010B01027 CADILAHC Pharmaceuticals EluxadolineTablets